The Androgen Thesis

"30–40% of men over 45 have biochemically low testosterone. The vast majority remain undiagnosed."

The testosterone deficiency landscape has undergone a clinical paradigm shift over the past decade. What was historically addressed only in catastrophic primary hypogonadism is now recognised as a significant contributor to the global burden of metabolic syndrome, cardiovascular risk, and quality-of-life impairment in men over 35. The testosterone replacement therapy (TRT) conversation has moved from endocrinology subspecialty to primary care — and the commercial market has followed.

The ester portfolio represents a clinical science of its own. Different ester bonds — undecanoate, enanthate, cypionate, propionate, decanoate — produce different half-lives, release kinetics, and injection frequency requirements. A quarterly undecanoate injection (Nebido® protocol) and a weekly propionate injection are chemically the same active molecule in different pharmacokinetic packages. Selecting the right ester is matching the therapy to the patient's physiology, lifestyle, and clinical monitoring capability.

Manufacturing testosterone APIs to GMP specification for controlled substance markets requires a different organisational infrastructure than standard pharmaceutical API production. Controlled substance licences, import/export permits, batch documentation for regulatory authorities, and supply chain traceability are pre-conditions — not afterthoughts. Polysacc's capability in this category reflects a compliance infrastructure that supports legitimate pharmaceutical supply chains to regulated markets globally.